阿托伐他汀对急性冠脉综合征患者血浆纤维蛋白原和C反应蛋白的影响

Effects of atorvastatin on plasma fibrinogen and C-reactive protein levels in patients with acute coronary syndrome

目的:观察阿托伐他汀治疗对于急性冠脉综合征患者血浆纤维蛋白原和C反应蛋白的影响。方法:本试验采用前瞻性开放性病例对照研究,将84例急性冠脉综合征患者随机分为2组:A组(41例)采用常规治疗;B组(43例)在常规药物治疗基础上,加用阿托伐他汀(20 mg/d)治疗,在治疗前以及治疗2个月后检测患者血浆纤维蛋白原及超敏C反应蛋白水平。结果:常规治疗对血浆纤维蛋白原和超敏C反应蛋白水平无明显影响;阿托伐他汀不但能降低血浆纤维蛋白原水平,还显著降低C反应蛋白水平。结论:阿托伐他汀改善急性冠脉综合征患者血液流变学,并具有抗炎作用,对于抑制心肌缺血的进展具有良好作用。

Objective：To investigate the effects of atmwastatin on plasma fibrinogen and C - reactive protein （CRP） levels in patients with acute coronary syndrome. Methods ： Eighty - four patients with acute coronary syndrome were enrolled in our study, and divided into 2 groups at random：Group A （41 subjects） were treated with conventional therapy, and Group B （43 subjects） were trea- ted with atorvastatin （20mg/d）combined with conventional therapy. They all received the treatment for 2 months. Plasma CRP and fi- brinogen levels were determined at baseline and after treatment. Results： Conventional therapy had no obvious effects on fibrinogen or CRP levels, administration of atorvastatin combined with conventional therapy could not only lower fibrinogen, but also significantly decreased CRP levels. Conclusions： Atorvastatin could improve the henmrheology of patients with acute coronary syndrome and inhibit inflammation, which may contribute to the prevention of advancement of myocardial ischemia.